Clobetasone

Evidence Level: L5

Predicted Indications: 10

Clobetasone

Pharmacist Assessment Report

Clobetasone: From Topical Corticosteroid-Responsive Skin Conditions to Primary Cutaneous T-Cell Lymphoma

One-Sentence Summary

Clobetasone is a moderate-potency topical corticosteroid marketed in India in cream and ointment form. The TxGNN model predicts it may be useful for primary cutaneous T-cell lymphoma (score 0.9997), but there are currently 0 clinical trials and 0 publications supporting this prediction, so it remains a model-based hypothesis only.

Quick Overview

Item	Content
Original Indication	Not specified in the available licence data
Predicted New Indication	Primary cutaneous T-cell lymphoma
TxGNN Prediction Score	0.9997
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data
Number of Listed Products	at least 20
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known pharmacology, clobetasone is a moderate-potency topical corticosteroid that acts through the glucocorticoid receptor, producing anti-inflammatory and immunosuppressive effects in the skin.

Topical corticosteroids are used as skin-directed therapy for early-stage mycosis fungoides, the most common subtype of cutaneous T-cell lymphoma (CTCL). A symptomatic benefit (reduced inflammation, itch and plaque activity) is therefore plausible. However, higher-potency agents such as clobetasol are the ones typically studied for this purpose, and no data specific to clobetasone were supplied.

The other top predictions are weaker. Sezary syndrome is a leukaemic, systemic disease, so a topical moderate-potency agent is unlikely to modify it. Primary cutaneous B-cell lymphoma and granulomatous slack skin disease are doubtful or unsupported. Several predictions (Crohn’s colitis, nephrotic syndrome, adrenocortical insufficiency) appear to reflect a corticosteroid class association rather than a feasible use of a topical skin product. Cystic teratoma and spinal cord dermoid cyst have no plausible mechanism; their scores come from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

India Market Information

Clobetasone is marketed in India as single-ingredient licences (20 valid, none cancelled), all in topical forms. The approved indication text is not recorded for any of the licences. The first five are listed below.

Authorization Number	Product Name	Dosage Form	Approved Indication
136517	Miclogenta Cream	Tube of 5 gm cream	Not specified
150645	Nadoxin-C Cream	Tube of 10 gm cream	Not specified
27677	Butesone Cream	Tube of 15 gm cream	Not specified
44302	Clodis GM Cream	Tube of 15 gm cream	Not specified
36746	Clomed M Cream	Tube of 10 gm cream	Not specified

Safety Considerations

Please refer to the package insert for safety information.

One point from the prediction analysis is worth noting: topical corticosteroids can suppress the hypothalamic-pituitary-adrenal (HPA) axis, particularly with extensive or prolonged use. For the adrenocortical insufficiency prediction, this is more a safety concern than a therapeutic opportunity.

Conclusion and Next Steps

Decision: Hold

Rationale: The only support is a TxGNN prediction (L5), with no clinical trials or literature for clobetasone. The mechanism is plausible only as symptomatic skin-directed therapy in early-stage CTCL, where higher-potency corticosteroids are the usual choice. Package insert safety information has not been obtained.

To proceed, the following is needed:

Package insert warnings and contraindications from the India regulatory source (currently blocking for safety screening)
Mechanism of action data from DrugBank
Approved indication text for the Indian licences
A targeted literature search on topical corticosteroids, and clobetasone specifically, in early-stage mycosis fungoides / CTCL
A comparison with higher-potency corticosteroids to see whether a moderate-potency agent offers any advantage (for example, a better safety profile)
Route and formulation compatibility assessment for lymphoma indications
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.